Currently, Orchid Pharma is trading under the T group on the BSE. In the T2T segment, each trade has to result in delivery and no intra-day netting of positions is allowed.
According to the latest shareholding pattern data, the promoter Dhanuka Laboratories held a 98.04 percent stake in Orchid Pharma. The public shareholders held a mere 2 percent holding, of which, 1 percent stake is with the financial institutions and banks, while individual shareholders held a 0.55 percent stake in the company, the data shows.
On March 31, 2020, the resolution plan under Corporate Insolvency Resolution Process (CIRP) has been implemented and the Board has been re-constituted with the members nominated by Dhanuka Laboratories, Haryana, India, the resolution applicant.
Read more